Meanwhile, A phase II study of 55 patients with locally advanced or metastatic EGFR/ALK wild-type NSCLC who had failed first-line anti-PD-1/L1 therapy, with or without platinum-based chemotherapy, found that SI-B001 plus docetaxel demonstrated antitumor activity. This evidence concerns the gene ALK and non-small cell lung carcinoma.